Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann, M.D., will participate in a fireside chat during the LifeSci Partners’ virtual Immunology and Inflammation Symposium on May 10-11, 2022. The chat is scheduled for 12:00 PM Eastern Time on May 10. Interested parties can access the webcast through the Investor Relations section of the company's website at www.immunovant.com. Immunovant specializes in treating autoimmune diseases and is known for its innovative therapies, including the investigational compound batoclimab.

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at LifeSci Partners’ virtual Immunology and Inflammation (I&I) Symposium, taking place May 10^th-11^th, 2022.

LifeSci Partners Immunology and Inflammation Symposium fireside chat details:

Date:	Tuesday, May 10th, 2022
Time:	12:00pm Eastern Time
Webcast:	The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). Designed to be optimized as a simple, subcutaneous injection with dosing that can be tailored based on disease severity and stage, batoclimab may reduce immunoglobin G (IgG) antibodies that cause inflammation and disease. For additional information on the Company, please visit www.immunovant.com.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

 

FAQ

When will Immunovant's CEO participate in the LifeSci Partners Symposium?

Immunovant's CEO Pete Salzmann will participate in the LifeSci Partners Symposium on May 10, 2022, at 12:00 PM Eastern Time.

What is the focus of the LifeSci Partners Immunology and Inflammation Symposium?

The LifeSci Partners Immunology and Inflammation Symposium focuses on advancements in immunology and inflammation treatments.

How can I access the webcast of Immunovant's fireside chat?

The webcast of Immunovant's fireside chat can be accessed via the Investor Relations section of their website at www.immunovant.com.

What is batoclimab and its significance to Immunovant?

Batoclimab is an investigational compound developed by Immunovant targeting autoimmune diseases, specifically designed as a subcutaneous injection.

What is the date and time of the fireside chat featuring Immunovant's CEO?

The fireside chat with Immunovant's CEO is scheduled for May 10, 2022, at 12:00 PM Eastern Time.